Sight Sciences offers a discounted, high-gross-margin med-tech turnaround with upside driven by TearCare reimbursement expansion, OMNI stabilization, and underappreciated litigation optionality.
Overview
Sight Sciences, Inc. (SGHT) is an ophthalmic med-tech company commercializing implant-free interventional products for open-angle glaucoma and evaporative dry eye disease, with revenue primarily generated from device sales and high-margin consumables in the U.S. The core investment debate is whether the company can convert its differentiated clinical platforms into sustained commercial scale while containing cash burn. **The business is showing an early operational inflection:** Q1 2026 revenue rose 12.5% year over year to $19.7 million, above consensus of roughly $18.47 million to $18.55 million, while dry eye revenue surged 244% to $1.35 million on improving reimbursement and utilization. **The most important catalyst is TearCare reimbursement expansion,** especially after Novitas and First Coast set approximately $1,142 carrier-priced reimbursement for CPT 0563T, covering 10.4 million Medicare lives. OMNI also remains resilient despite late-2024 LCD headwinds in cataract-MIGS combinations, and OMNI Ultra is a pipeline catalyst for late 2026. Financially, gross margin remains strong at 86.2%, cash stood at $85.0 million against $40.0 million of term debt, and Q1 cash usage improved 40% to $7.0 million. Valuation appears discounted at 3.7x TTM sales versus an 8.5x peer average, but investors still face risks around ongoing losses, patent appeals, and reimbursement execution.